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self-reported health status, Activities of Daily Living, and Instru-
mental Activities of Daily Living. However, estimates of the
effect of prescription drug coverage on prescription use that
control for selection are much smaller than those previously
reported. CONCLUSION: Studies that purport to analyze the
effect of drug coverage on utilization or health using observa-
tional data needs to account for selection bias associated with
such coverage.
PATIENT-REPORTED OUTCOMES I
PR1
A BAYESIAN ESTIMATION OF AN AVERAGE SF-6D
PREFERENCE BASED SCORE FROM COMMONLY REPORTED
SF-12 STATISTICS
Hanmer J, Fryback DG
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OBJECTIVES: To construct an algorithm which converts statis-
tics commonly reported in publications with the SF-12 health
status measure to an average SF-6D preference based score.
METHODS: We used SF-12 data from the 2002 Medical Expen-
ditures Panel Survey. We presumed commonly published sufﬁ-
cient statistics would include average age, sex, physical
component score (PCS), and mental component score (MCS). All
combinations of these variables were used as predictors in
models built with WinBUGS 1.4. Model ﬁt was evaluated with
the Deviance Information Criterion (DIC). The best ﬁt model
was also evaluated using R-square for comparison to other algo-
rithms that convert SF-12 summary scores to preference scores.
RESULTS: We used all respondents with PCS and MCS scores
(n = 20,206). The best ﬁt model included age, sex, PCS, and MCS
as predictor variables (DIC = -67,434). The model was SF-6D =
-0.001544 - 0.002173*female + 0.000144*age + 0.008097*
MCS + 0.00816*PCS. The R-square of this model (0.88) was
substantially better than models that convert to EQ5D summary
scores developed by Lawrence et al (0.61) or Franks et al (0.63
and 0.59) or to HUI Mark 3 summary scores by Franks et al
(0.51) or Sengupta et al (0.55). Because this model does not
include power or interaction terms, knowing the average age,
PCS score, MCS score, and the percent whom are female in a
sample is sufﬁcient to predict an average SF-6D score. The resid-
ual from directly calculated SF6D scores drops dramatically as
group size increases; the standard deviation of residual size is
0.046 for 1 subject, 0.014 for 10 subjects, 0.006 for 50 subjects,
0.005 for 100 subjects, and approaches an asymptote of 0.003
with more than 200 subjects. CONCLUSIONS: Commonly
reported summary statistics from previously published articles
provide sufﬁcient information for estimating an average SF-6D
score without accessing individual level data.
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OBJECTIVES: To compare conceptual models, empirical mea-
surement, and results of alternative methods for measuring
patients’ willingness to trade off severe adverse event risks for
speciﬁed health gains. METHODS: We deﬁne and compare the
theoretical foundations of standard gamble (SG) and multi-
attribute conjoint analysis (CA) methods. SG derives from von
Neumann-Morgenstern expected-utility theory, while CA applies
McFadden random-utility theory to hypothetical choices. We
deﬁne theoretical conditions under which the two methods
provide equivalent health-preference measures, including linear-
ity, separability, and risk-neutrality. We evaluate accepted empir-
ical methods used in SG and CA studies and propose methods
for incorporating risks as CA treatment attributes. We then
compare empirical maximum acceptable-risk estimates from CA
studies of multiple sclerosis and Crohn’s disease patients with
and without restrictive SG assumptions, as well as with pub-
lished SG estimates from other disease interventions. RESULTS:
We ﬁnd that SG can be used to estimate MARs for speciﬁc health
outcomes only by imposing more restrictive assumptions on
patient preferences than CA methods require. We show that CA
methods can be used to test various theoretical restrictions
imposed by the SG assumptions and ﬁnd that risk neutrality and
linearity are rejected statistically in most cases. By imposing SG
assumptions on CA results and by comparing CA results to pub-
lished SG estimates for chronic conditions, we ﬁnd that SG
assumptions increase MAR estimates by 20% to 150% relative
to those obtained by CA methods. CONCLUSIONS: CA
methods can be used to replicate SG tradeoff tasks and to test
the restrictions required to interpret SG estimates as risk-prefer-
ence measures. CA offers a more ﬂexible and conceptually rig-
orous method than SG as conventionally applied for measuring
treatment preferences and risk-beneﬁt tradeoffs. Most impor-
tantly, multiattribute CA methods can more realistically simulate
clinically relevant risk-beneﬁt tradeoff choices to improve the
validity and reliability of preference estimates.
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OBJECTIVES: To document whether there are fundamental
racial differences in patients’ perception of the preference-based
utility assessment for health-related quality of life. METHODS:
Secondary data analysis was conducted using the 2003 Medical
Expenditure Panel Survey (MEPS), a nationally representative
sample of 20,428 people with their concurrent EQ-5D scores
reported. Given the upper-bound of preference-based scores at
1.0, a two-part model was derived to identify the relationship
between race and the preference-based utility score after con-
trolling for individual demographic covariates, comorbidity
proﬁle, and functional and activity limitations. Logit models
were employed to predict the probability of “no problems” for
speciﬁc attribute in EQ-5D. In order to generalize the results to
the whole US population, the complex survey sampling design
of MEPS was taken into account using the speciﬁed sample
weight, variance estimation stratum and primary sampling unit.
RESULTS: Compared with Whites, Blacks were less likely to per-
ceive themselves in full health (utility score of 1.0) by 3.5 per-
centage points (p < 0.01), holding all other factors constant. For
those who did not perceive full health (51%), Blacks on average
perceived themselves 0.037 less than Whites in the utility assess-
ment (p < 0.0001). Even after controlling for education and
income, racial difference remained signiﬁcant. Among the ﬁve
attributes of EQ-5D, self-care was the major contributor of the
racial difference for utility assessment. Anxiety/depression was
the only domain which did not have signiﬁcant difference. CON-
CLUSIONS: This study adds to the literature of health-related
quality of life by providing empirical evidence at the national
level to demonstrate the racial differences for preference-based
utility assessment. Health researchers need to be aware that
Blacks are likely to perceive having a lower health-related quality
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of life than Whites even when their health status is equal. This
may lead to racial differences regarding optimal decision making
and conclusions based on cost-effectiveness analysis.
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Pain is widespread. Many scales have been used for measuring
clinical outcomes of pain, but few are preference-based instru-
ments. OBJECTIVES: To compare scores derived from the Box-
Score-11 (BS-11), a clinical scale widely used for measuring pain,
and the Pain attribute (PA) of the Health Utilities Index (HUI-
III), a preference-based instrument. METHODS: Patients (≥18
years) were recruited from pain clinics in four Canadian metro-
politan areas (Toronto, Ottawa, Edmonton, Vancouver) and
were administered both scales, assessing their average pain level
over the previous four weeks. Kendall’s tau-b was calculated
between score sets and the proportions of the scores derived from
the BS-11 that mapped onto each of the ﬁve PA scores of the
HUI-III. RESULTS: Of 516 questionnaires completed, 6 had
missing information, leaving 510 for analysis. The average age
was 49.5 ± 11.9 years; 70% were female. Tau-b was reasonably
large and statistically = 0.685, Ptsigniﬁcant between the scales
(<0.001). No patients scored 0 on either scale, as only patients
with pain were included. Two patients scored 1 and yielded
inconclusive results. All, except one, of the remaining BS-11
scores mapped at ≥60% onto PA scores of the HUI-III respec-
tively: 2 to 2, 3 to 2, 4 to 3, 5 to 3, 7 to 4, 8 to 4, 9 to 5 and
10 to 5; 6 on the BS-11 was mapped onto 4 on the HUI-III with
53% of answers. Scores 2 and 10 had best mapping (88% and
94%). The overall correspondence was considered excellent.
CONCLUSIONS: This study demonstrated that scores from the
BS-11 can be mapped onto the PA component of the HUI-III.
RESPIRATORY DISORDERS
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OBJECTIVES: This study examined trends in physician-pre-
scribing of medications for children with sleep difﬁculties in out-
patient settings in the Unites States. Additionally, this study also
explored the incidence of physician-prescribing patterns of high
abuse-potential medications for children, and compared pre-
scribing trends in children versus adults. METHODS: This cross-
sectional study used data from the National Ambulatory Medical
Care Survey (NAMCS) from 1993–2003. Patient aged <18 years
were included in the study sample. We compared this sample to
the sample of patients aged 18 years and older. Ofﬁce visits were
considered related to sleep difﬁculties if relevant ICD-9 codes
were recorded and if sleep difﬁculties was reported as the reason
for the visit. Medications were retrieved using the NAMCS drug
codes, and all analyses were weighted to make national esti-
mates. RESULTS: From 1993 to 2003, approximately one
million visits were made for sleep-related difﬁculty in children.
Nearly two-thirds (63%) of these visits were related to male chil-
dren and 26% of these visits were by children aged less than
three years. Family practice and internal medicine physicians
accounted for 21% of the patient visits. Only 2% of visits in
children resulted in a prescription for a medication compared to
over half the adult population. Similar trends were observed with
the prescription of high-abuse potential medications, where
adults were 35 times more likely to receive prescriptions of med-
ications with very high abuse potential. There were no time-
related differences observed in these prescribing patterns.
CONCLUSION: The ﬁndings of this study seem to suggest that
a great deal of caution is being exercised by physicians while 
prescribing medications for sleep difﬁculties in children in US
outpatient settings, since most of the visits do not result in med-
ication prescription, unlike trends observed in adult patients with
similar diagnoses in the same treatment setting.
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OBJECTIVE: To compare treatment costs and cost-effectiveness
of telithromycin versus other commonly-prescribed therapies for
community-acquired pneumonia (CAP). METHODS: We devel-
oped an economic model to estimate the costs of treating CAP
using a utilization-based deﬁnition of therapy failure, deﬁned 
as respiratory-related hospitalization, ER visit, receipt of 
second antibiotic, or >1 return ofﬁce visits within 30 days of
therapy initiation. Probability of failure was estimated for 
amoxicillin/clauvulanate, azithromycin, clarithromycin and 
ﬂuoroquinolones from a longitudinal database; estimates were
adjusted using propensity scores based on patient characteristics
and prior utilization patterns. Probabilities for telithromycin
were estimated using relative risks for each outcome versus clar-
ithromycin from a published clinical trial. Costs of initial therapy
and costs of failure were derived from the longitudinal database;
probability of clinical cure was estimated from published clini-
cal trials. The model was used to estimate 30-day direct treat-
ment costs, and cost-effectiveness as incremental cost per clinical
cure. We used second-order Monte Carlo simulation to evaluate
the effect of uncertainty in key model parameters on our ﬁnd-
ings. RESULTS: In base-case analyses, telithromycin had the
lowest overall treatment costs at $174/treated patient, followed
by azithromycin ($219), clarithromycin ($262) ﬂuoroquinolones
($315), and amoxicillin/clauvulanate ($340). Clarithromycin
had a slightly higher probability of clinical cure (92.1%) than
telithromycin (90.5%) but at an additional cost of $5444/cure.
Fluoroquinolones had a slightly higher probability of clinical
cure (92.3%) than clarithromycin at a cost of $24,098/cure.
Azithromycin and amoxicillin/clauvulanate were dominated.
Alternative analyses using AWP and WAC to estimate drug costs
yielded similar results. Probabilistic sensitivity analyses showed
telithromycin to be the least costly therapy in 88% of 1000 
simulations. Telithromycin was cost-effective at a threshold 
of $500/cure in 86% of simulations, and at a threshold of
$1000/cure in 83% of simulations. CONCLUSIONS:
Telithromycin appears to be a cost-effective treatment for CAP
versus amoxicillin/clauvulanate, azithromycin, clarithromycin
and ﬂuoroquinolones.
